Nxera Pharma Co., Ltd.
Received $3.6 Million Milestone from Centessa
Nexera Pharma has received a $3.6 million (approximately ¥565 million) milestone from Centessa and plans to record it as revenue in the fourth quarter of the fiscal year ending December 2025.
Key Figures
- Milestone Amount Received: $3.6 million (approximately ¥565 million)
- Revenue Recognition Period: Fiscal Year Ending December 2025 Q4
- Partner: Centessa Pharmaceuticals Limited
AI要約
Overview of Milestone Receipt
Nexera Pharma Co., Ltd. has received $3.6 million (approximately ¥565 million) following the achievement of an early development milestone for ORX142, an orexin receptor 2 (OX2R) agonist under development by partner Centessa Pharmaceuticals Limited. This amount will be recorded as revenue in the fourth quarter of the fiscal year ending December 2025.
Company Overview and Pipeline
Nexera Pharma is a technology-driven biopharmaceutical company developing a pipeline of over 30 products in-house and with partners using the NxWave™ drug discovery platform. The company focuses mainly on obesity and metabolic disorders, neurological and neuropsychiatric disorders, as well as immune and inflammatory diseases, and operates globally.
